BHIVA Audit 2021: hepatitis C and HIV coinfection

Welcome to the 2021 BHIVA national audit of hepatitis C and HIV co-infection. This comprises two elements:

- A brief survey of clinic arrangements for managing co-infected individuals this should be completed once for each HIV specialist care service
- A case-note review of adults (age 16 or over) living with HIV who are *currently* RNA-positive and infected with hepatitis C (HCV). Please complete the case-note review for all such individuals under the care of your HIV service, or the 40 most recent attenders if there are more than 40 in total.

If you make a mistake or wish to change an earlier answer, please do not use your browser "Back" button. Instead use the "Previous" button at the bottom of each questionnaire page.

Please direct any queries to BHIVA's clinical audit co-ordinator Hilary Curtis, hilary@regordane.net (mailto:hilary@regordane.net?subject=BHIVA%20audit%20query)

There are 46 questions in this survey.

Select questionnaire

The token/site-code you entered is for the following clinic or department: {TOKEN:ATTRIBUTE_1} {TOKEN:ATTRIBUTE_2} {TOKEN:ATTRIBUTE_3}	
Please choose all that apply:	
i lease choose an that apply.	
Please tick to confirm this is the correct clinic/department	
The questionnaire will appear if the box is ticked. If yours is not the department/clinic named above, then please consult your service's lead for HIV clinical audit to request the correct token/site-code. If s/he is not able to provide this, then please contact BHIVA's clinical audit co-ordinator, Hilary Curtis, hilary@regordane.net (mailto:hilary@regordane.net?subject=BHIVA%20site-code%20query) 07984 239556.	f
If the department/clinic above is correct except for minor details, eg a change of name, then please tick the box to proceed.	

Which questionnaire do you wish to complete? *
Only answer this question if the following conditions are met:
Answer was at question '1 [TokenCheck]' (The token/site-code you entered is for the following clinic or department: {TOKEN:ATTRIBUTE_1} {TOKEN:ATTRIBUTE_2} {TOKEN:ATTRIBUTE_3})
Please choose only one of the following:
Brief survey of clinic arrangements for management of hepatitis/HIV co-infection
Case-note review of individuals RNA-positive for hepatitis C and infected with HIV
Characteristics of audited individual
What was the result of this individual's most recent test for hepatitis C RNA? *
Please choose only one of the following:
○ Detectable
○ Not detectable
○ Not recorded
This question REQUIRES an answer.
Only answer this question if the following conditions are met: Answer was 'Not detectable' <i>or</i> 'Not recorded' at question '3 [Eligibility]' (What was the result of this individual's most recent test for hepatitis C RNA?)
This individual is not eligible for inclusion in the audit. Only adults (16 or over) living with HIV and RNA-positive for hepatitis C are eligible.
Current gender:
Only answer this question if the following conditions are met: Eligible for audit
Please choose only one of the following:
Male (including trans)
Female (including trans)
Non-binary or other
O Declined to say

(

Does individual identify as trans?				
Only answer this question if the following conditions are met: Eligible for audit				
Please choose only one of the following:				
Yes				
○ No				
Not recorded				
Age in years: Only answer this question if the following conditions are met: Eligible for audit Please write your answer here:				
Exposure factors by which this individual may have acquired HIV and blood-borne infections (tick ALL that apply): Only answer this question if the following conditions are met: Eligible for audit				
Please choose all that apply:				
MSM				
Heterosexual sex				
Injecting non-chemsex drugs				
Injecting chemsex drugs				
Blood or blood products				
Not known				
Other, please state::				

Behaviours in which this individual <i>currently</i> engages (tick ALL that apply):			
Only answer this question if the following conditions are met: Eligible for audit			
Please choose all that apply:			
MSM Heterosexual sex Injecting non-chemsex drugs Injecting chemsex drugs Non-injecting use of chemsex drugs			
Most recent serology Only answer this question if the Eligible for audit Please choose the appropriate	following conditions a	re met:	
	Positive	Negative	Not recorded
Hepatitis B core antibody (anti-HBc)	\bigcirc	\circ	
Hepatitis B surface antibody (anti-HBs) - "positive" means 10 mIU or above			
Hepatitis B surface antigen (HBsAg)	0	0	
When was the anti-H Only answer this question if the anti-HBs positive, HBsAg negative. Please choose only one of the Within last 18 months 18 months to 3 years Not recorded as done within	e following conditions a tive, and anti-HBc nega following:	re met:	

Please tick if this individual:				
Only answer this question if the following conditions are met: Negative for anti-HBc, anti-HBs and HBsAg				
Please choose only one of the following:				
Was previously hepatitis B core antibody (anti-HBc) positive but has lost antibody				
Is a known poor responder to hepatitis B vaccination				
Hepatitis B DNA status:				
Only answer this question if the following conditions are met: HBsAg positive				
Please choose only one of the following:				
O Detectable, greater than 2000 IU/ml				
O Detectable, lower than 2000 IU/ml				
Not detectable				
Not recorded				
Management of hepatitis C infection				
What is the HCV genotype, if known?				
Please choose only one of the following:				
<u> </u>				
<u></u>				
<u></u>				
<u>5</u>				
<u>6</u>				
Not known or not recorded				

Has this individual received treatment for hepatitis C infection? Please choose only one of the following:
 No - this individual has not been treated for hepatitis C Yes - has been or is currently being treated Not recorded whether treated Answer "Yes" if a course of treatment was started but not completed.
When was the individual (last) treated for hepatitis C? Only answer this question if the following conditions are met: Treated for HCV Please choose only one of the following: Treatment is currently in progress Most recent course of treatment started during 2018-21 Most recent course started during 2015-17 Most recent course started during 2014 or earlier Not recorded If treated more than once, answer for the most recent course of treatment.

What was the regimen for the current or most recent course of treatment?			
Only answer this question if the following conditions are met: Most recent treatment started 2018 or later			
Please choose only one of the following:			
Elbasvir/Grazoprevir (Zepatier)			
Glecaprevir/Pibrentasvir (Maviret)			
Sofosbuvir/Velpatasvir (Epclusa) without Ribavirin (Copegus)			
Sofosbuvir/Velpatasvir (Epclusa) with Ribavirin (Copegus)			
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi)			
Sofosbuvir/Ledipasvir (Harvoni) with or without Ribavirin (Copegus)			
Ombitasvir/Paritaprevir/RTV (Viekirax) with Ribavirin (Copegus)			
Ombitasvir/Paritaprevir/RTV (Viekirax) + Dasabuvir (Exviera) with or without Ribavirin (Copegus)			
Sofosbuvir (Sovaldi) + Daclatasvir (Daklinza) with or without Ribavirin (Copegus)			
○ Not recorded			
Other, please state:			
Was the current or most recent course of treatment provided through participation in a clinical trial? Only answer this question if the following conditions are met: Most recent treatment started 2018 or later Please choose only one of the following: Yes No No Not recorded			

Did this individual need to modify ARVs to avoid interactions with drugs used in the current or most recent course of hepatitis C treatment? Only answer this question if the following conditions are met: Most recent treatment started 2018 or later Please choose only one of the following: Yes No No Not sure			
Why does this individual have detectable HCV RNA despite having received treatment?			
Only answer this question if the following conditions are met: Treated			
Please choose only one of the following:			
Re-infected after previous successful treatment			
The (most recent) course of treatment was completed but did not achieve sustained virological response (SVR)			
The (most recent) course of treatment was not completed and did not achieve SVR			
Other reason(s), please state:			
Is re-treatment planned?			
Only answer this question if the following conditions are met: Re-infected after previous treatment			
Please choose only one of the following:			
Re-infection is recent, waiting for possible spontaneous clearance before considering retreatment			
Re-treatment is currently planned			
In accordance with clinic policy, re-treatment is not currently planned			
Individual does not wish to be re-treated			
Other, please comment:			

Why has this individual not received treatment for hepatitis C infection? Please tick all that apply and expand your answer(s) with comments if you wish - we would like to understand the reasons as fully as possible. Only answer this question if the following conditions are met: Not treated
Please choose all that apply and provide a comment:
Recently acquired hepatitis C infection (within last 6 months) which may clear spontaneously
Treatment is currently planned
Individual does not believe treatment is effective
Individual believes treatment would be toxic
Individual does not wish to be treated - please add reasons, if known
Individual is considered unlikely to adhere well to treatment
Individual is likely to be at significant risk of re-infection following treatment
Individual is not engaging in care
Individual is not contactable - eg no phone
Other:

	Yes	No	Not sure
ndividual has received counselling regarding nepatitis C transmission risk factors and safe sex?	0	0	
Individual has been offered harm reduction support (or this is recorded as not necessary)?		0	0
Partner notification has been conducted (or recorded as not necessary) for hepatitis C as well as HIV?	0	0	0
When was the last re		/discussion abo	out alcohol ι
		/discussion abo	out alcohol u
Please choose only one of the Within past 9 months 9-18 months ago 18 months to 3 years ago Longer, or none recorded	following:	discussion abo	out alcohol u
Please choose only one of the Within past 9 months 9-18 months ago 18 months to 3 years ago Longer, or none recorded When was fibrosis la	following:	discussion abo	out alcohol u
Please choose only one of the Within past 9 months 9-18 months ago 18 months to 3 years ago Longer, or none recorded	st assessed? following:	discussion abo	out alcohol u
Within past 9 months 9-18 months ago 18 months to 3 years ago Longer, or none recorded When was fibrosis la	st assessed? following:	discussion abo	out alcohol ι

Is it documented that:

Only analysis this !!	if the fellowing conditions are rest.			
Only answer this question if the following conditions are met: Fibrosis assessment has been done				
Please choose all that app	ly:			
Liver biopsy				
Elastography (eg Fibro	oscan)			
Blood markers (eg FIB	4)			
Not recorded				
Fibrosis stage:				
Only answer this question i Fibrosis assessment has b	if the following conditions are met: een done			
Please choose only one of	f the following:			
Normal				
Minimal or mild fibrosis	5			
Moderate fibrosis				
Severe fibrosis/cirrhosi	is			
Not recorded				
Please select the	option that best describes arrangements for ent of this individual:			
Please choose only one of	f the following:			
An HIV specialist and a	a specialist hepatologist share care through an agreed care plan			
	a specialist hepatologist share care, but without an agreed plan			
	an interest in hepatitis provides care			
Other, please describe				

How is information shared between the HIV and hepatology specialists? Only answer this question if the following conditions are met: Care is shared between HIV specialist and specialist hepatologist Please choose only one of the following:
Both specialists record information in the same patient record (eg within one trust) Communication is via letter/email or similar Other, please describe: Select the first answer that applies.
When was the most recent letter/email/similar from the hepatologist to the HIV specialist? Only answer this question if the following conditions are met: Communication is via letter/email etc Please choose only one of the following: Within last 6 months 6-12 months ago 12-18 months ago Longer, or none recorded
Is it documented that the individual has either been vaccinated against hepatitis A or is naturally immune (IgG positive)? Please choose only one of the following: Yes No No Not sure

When was liver ultrasound last performed?					
Only answer this question if the following conditions are met: Individual has moderate or severe fibrosis or cirrhosis					
Please choose only one of the following: Within past 9 months					
Not recorded as done					
○ Not known					
When was alpha-fetoprotein last measured?					
Only answer this question if the following conditions are met: Individual has moderate or severe fibrosis or cirrhosis					
Please choose only one of the following:					
Within past 9 months					
9-18 months ago					
One but more than 18 months ago					
Not recorded as done					
○ Not known					
Has the individual been diagnosed with hepatoma?					
Only answer this question if the following conditions are met: Individual has moderate or severe fibrosis or cirrhosis					
Please choose only one of the following:					
Yes					
○ No					
○ Not sure					

Has upper GI endoscopy been performed? Only answer this question if the following conditions are met: Individual has severe fibrosis/cirrhosis Please choose only one of the following: Yes							
						○ No	
						○ Not sur	e
	gns of decompensation occurred (ie encephalopathy,						
	and/or variceal haemorrhage)?						
•	er this question if the following conditions are met: as severe fibrosis/cirrhosis						
Please cho	ose only one of the following:						
Yes							
○ No							
O Not sur	e						
inic sı	urvey: management of HIV/hepatitis C co-infection						
What a	re the estimated numbers of people with HIV:						
What al	re the estimated numbers of people with HIV:						
What al	re the estimated numbers of people with HIV: e your answer(s) here:						
What al	re the estimated numbers of people with HIV: e your answer(s) here:						
What al	re the estimated numbers of people with HIV: e your answer(s) here: sed HIV care via your service/clinic within the last year?						
What all Please writh Who acces	re the estimated numbers of people with HIV: e your answer(s) here: sed HIV care via your service/clinic within the last year?						
What and Please write Who access Of these, wo	re the estimated numbers of people with HIV: e your answer(s) here: sed HIV care via your service/clinic within the last year? ho are antibody positive for hepatitis C?						

Which of the following best describes your service's arrangements for management of hepatitis B/C in individuals with HIV? Please choose only one of the following: Our service is a regional specialist or referral centre for HIV/hepatitis co-infection Managed via a co-infection clinic within the HIV service (complex cases may be referred) Referred to local hepatology service Referred to regional specialist co-infection clinic Other, please describe:
Is there a regular joint clinic led by specialists in both HIV and hepatology? Only answer this question if the following conditions are met: Co-infected individuals are managed within the HIV service Please choose only one of the following: Yes No No
Which of the following best describes current access to repeat hepatitis C treatment for individuals who become <i>re-infected</i> following previous successful treatment? Please choose only one of the following: Confident that re-treatment would be offered in most cases Re-treatment might be offered in some cases depending on individual circumstances Re-treatment would not ordinarily be offered Not sure

Does your clinic system allow you to accurately update HARS if an individual's hepatitis C status changes from infected to uninfected (ie clearance)? Please choose only one of the following:					
Yes No					
Not sure					
Not applicable - outside England and not using HARS					
Thot applicable - outside England and not doing 11/11/0					
Does your service routinely conduct partner notification for hepatitis C? Please choose only one of the following: Yes, we do this for both hepatitis C and HIV We do this routinely for HIV but not for hepatitis C Partner notification is done elsewhere for both HIV and hepatitis C Not sure					
Is there provision loca	ally for?				
Please choose the appropriate response for each item:					
	Yes	No	Not sure		
Peer support for hepatitis C (not just for HIV)?	\circ	\circ			
Home/community visits to encourage care engagement for people with hepatitis C?					

Please describe any specific measures your service has taken to encourage uptake of hepatitis C treatment among people coinfected with HIV:			
Please write your answer here:			
If you wish to comment specifically on how the covid-19 pandemic has affected management of hepatitis co-infection for your HIV patients, then please do so here:			
Please write your answer here:			

Submit

When you are satisfied with your response, please click the "Submit" button - your answers are not saved until you do so.

Thank you. Your answers have been saved. If you would like a copy for your own records, to print or save as a pdf, then please **right**-click on "Print your answers" **now** to open the completed questionnaire in a new tab or window, before clicking any other link.

Otherwise:

- Please click here if you wish to return to the start to enter data for a different patient or complete the clinic survey
 - (https://surveys.bhiva.org/index.php/survey/index/sid/131697/newtest/Y/lang/en/token/{TOKEN:TOKEN})
- Or please click here to go to the BHIVA website. (https://www.bhiva.org/)

Submit your survey.

Thank you for completing this survey.